ALTS
TechnologyALT5 Sigma Corporation
$1.51
+$0.30 (+24.79%)
Jan 5, 2026
Price History (1Y)
Analysis
ALT5 Sigma Corporation is a technology company operating in the software application industry. With a market capitalization of $188.67 million and 10 employees, it is a relatively small player in its sector. The company's financial health indicates significant challenges. Its net income has been negative at $-13,415,000 over the trailing twelve months, resulting in an operating margin of -32.8% and a profit margin of -74.9%. This is also reflected in its return on equity (ROE) of -44.8%, which suggests that shareholders are not earning returns from their investment. ALT5 Sigma Corporation has $22.73 million in debt, compared to its cash balance of $9.56 million. The company's valuation metrics indicate a complex situation. Its price-to-book ratio is 3.55 and its price-to-sales ratio is 8.48, but the EV/EBITDA ratio is -66.27, indicating significant losses relative to market capitalization. Revenue growth has been substantial at 194.1%, but earnings growth is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About ALT5 Sigma Corporation
ALT5 Sigma Corporation, together with its subsidiaries, provides blockchain-powered technologies worldwide. It operates through Fintech and Biotechnology segments. The company engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. Its products include ALT 5 Prime, an electronic over-the-counter trading platform for the buying and selling of digital assets; and ALT 5 Pay, a crypto-currency payment gateway that enables merchants to accept and make crypto currency payments or integrate the payment platform into their application. The company is also involved identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies for the treatment of pain and addiction. In addition, it develops JAN 101, an oral and sustained-release pharmaceutical composition of sodium nitrite that has completed Phase 2a clinical trial to treat peripheral arterial disease and pain; and JAN123, a formulation of low-dose naltrexone for the treatment of chronic regional pain syndrome. The company was formerly known as JanOne Inc. and changed its name to ALT5 Sigma Corporation in July 2024. ALT5 Sigma Corporation was founded in 1976 and is based in Las Vegas, Nevada.
Visit website →Key Statistics
- Market Cap
- $188.67M
- P/E Ratio
- N/A
- 52-Week High
- $10.95
- 52-Week Low
- $1.08
- Avg Volume
- 4.53M
- Beta
- 1.66
Company Info
- Industry
- Software - Application
- Exchange
- NCM
- Country
- United States
- Employees
- 10